This product combines two distinct research peptides, BPC-157 and TB-500, in a single lyophilised preparation. AminoOptimization Group supplies the blend as a lyophilised research powder in 10 mg and 20 mg presentations, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is BPC-157 / TB-500 Blend?
BPC-157 / TB-500 Blend is a combination research product, not a single molecular entity. It pairs two independently synthesised and independently characterised peptides — BPC-157 and TB-500 — in one vial. Because the vial contains two distinct peptides rather than a single fused compound, it has no single CAS number, molecular formula, or molecular weight; those fields are not applicable to a combination product, and each peptide keeps its own identity within the mixture.
BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid chain — corresponding to a partial sequence identified within a protein isolated from human gastric juice, from which the name Body Protection Compound derives. Its stability across a wide pH range, including conditions that degrade most peptides, is one of the structural features most frequently noted in the literature, generally attributed to its short chain length and proline-rich sequence.
TB-500 is the trade name given to synthetic material corresponding to the active region of thymosin beta-4, a small, naturally occurring protein characterised for its role in regulating actin, the protein forming the cytoskeleton’s structural filaments. It belongs to the beta-thymosin family, a group distinguished from most peptides of comparable size by an actin-binding rather than a receptor-binding mode of action.
Specifications
- Compound: BPC-157 / TB-500 Blend
- CAS number: N/A (blend)
- Molecular formula: N/A (blend)
- Molecular weight: N/A (blend)
- Purity: 99% by HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 10 mg, 20 mg
- Physical form: White to off-white powder
- Classification: Research peptide blend — not for human or veterinary use
Research context
Published research on BPC-157 has examined its interactions with signalling pathways in tissue-level model systems, including work on nitric oxide synthase activity and vascular endothelial growth factor receptor signalling. Study designs have used it to investigate angiogenesis-related processes and fibroblast behaviour in vitro, and its resistance to enzymatic and acid degradation has made it a reference peptide in studies of gastrointestinal stability more broadly.
Thymosin beta-4 and TB-500 preparations appear in literature examining actin sequestration and cytoskeletal remodelling, and are used in cell-migration assays where researchers track how cells reorganise their internal filament networks in response to a stimulus. It also appears in comparative study designs alongside other actin-regulating proteins, where differences in binding kinetics are the variable under examination.
Because both peptides appear independently across overlapping areas of the research literature — angiogenesis, cell migration, and extracellular matrix signalling — some study designs examine them in combination to assess whether their documented mechanisms interact. This blend does not represent a fixed, published protocol; it packages the two peptides together for researchers designing their own comparative study work. None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work. Because this product combines two peptides in a single vial, both dissolve together when diluent is added.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed; full dissolution is expected within a few minutes at room temperature.
Working concentration is a function of how much diluent you add to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state, and brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Each lot is tested by high-performance liquid chromatography, and the purity figure shown above reflects analytical results for the specific lot supplied, not a generic specification. A Certificate of Analysis is available on request, including before purchase.
Purity by HPLC describes the proportion of target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested, and it is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation.
Frequently asked questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a short, 15-amino-acid peptide derived from a gastric-juice protein and studied for its stability and interactions with growth-factor-related signalling. TB-500 corresponds to the active region of thymosin beta-4, a larger actin-binding protein studied for its role in cytoskeletal regulation. They belong to different structural classes and are examined across different, though sometimes overlapping, areas of the literature.
Is the BPC-157 / TB-500 blend approved in Canada?
No. Neither peptide in this blend has been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. The product carries no DIN or NPN, its safety and efficacy for human or veterinary use have not been assessed, and it is supplied for laboratory research only.
Why are BPC-157 and TB-500 supplied together instead of separately?
The two peptides appear independently across overlapping areas of the research literature, and some study designs examine them in combination. Supplying them pre-combined is a matter of laboratory convenience; it does not indicate that the peptides are chemically joined or that a combined form has been separately characterised.
How much diluent should be used to reconstitute this blend?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.